Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 4/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415370 | 1.00 | CPB1 (0.54) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL28634160 | 0.89 | ALDH1A1 (0.52) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL28833984 | 0.88 | CPB1 (0.54) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL28833767 | 0.88 | CPB1 (0.54) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL21522663 | 0.87 | CTSK (0.60) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL29268593 | 0.87 | CTSK (0.60) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL29268591 | 0.87 | CTSK (0.60) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL6342264 | 0.86 | CPB1 (0.50) | CPB1ALDH1A1GAACTSKDPP4 | |
| SCHEMBL6713945 | 0.86 | CPB1 (0.53) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL19814180 | 0.86 | CPB1 (0.50) | CPB1ALDH1A1GAACTSKDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| CN-114980976-A | Covalent RAS inhibitors and uses thereof | 锐新医药公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | CPB1 2027/4885ALDH1A1 3445/4885GAA 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.